|

Capecitabine Oral Product Clinical Trials

2 actively recruiting trials across 1 location

Also known as: Active Comparator control group, Xeloda

Pipeline

Phase 2: 1Phase 3: 1

Top Sponsors

  • Herui Yao1
  • Abramson Cancer Center at Penn Medicine1

Indications

  • Cancer2
  • Metastatic Breast Cancer1
  • Neuroendocrine Tumor Grade 21
  • Neuroendocrine Tumors1
  • Liver Cancer1

Other1 trial

Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer
Phase 3

La Jolla, California1 trial

CapTemY90 for Grade 2/3 NET Liver Metastases

UC San Diego

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.